FrancophonIA/ELRC3.0 huggingface dataset:
English: Carbamazepine should be used with caution in combination with atazanavir.
Estonian: Ettevaatus on vajalik verapamiili samaaegsel kasutamisel koos atasanaviiriga.
English: Atazanavir/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
Estonian: Atasanaviir/RTV koos tenofoviirdisoproksiilfumaraadi/emtritsitabiiniga (fikseeritud annus 300 mg/200 mg tabletid üks kord ööpäevas).
English: 90 hard capsules.
Estonian: 30 kõvakapslit 90 kõvakapslit
English: Human experience of acute overdose with atazanavir is limited.
Estonian: Atasanaviiri ägedast üleannustamisest inimestel on andmeid piiratult.
English: Co-administration of nevirapine and atazanavir is not recommended (see section 4.4)
Estonian: Nevirapiini manustamine koos atasanaviiriga ei ole soovitatav (vt lõik 4.4)
English: Interaction
Estonian: Efektiivsus
English: BOTTLE LABEL FOR 300 MG HARD CAPSULES
Estonian: SILT 300 MG KÕVAKAPSLEID SISALDAVALE PUDELILE
English: This summary was last updated in 11-2014.
Estonian: Kokkuvõtte viimane uuendus: 11-2014.
English: Vargatef nintedanib
Estonian: Vargatef nintedaniib
English: The recommended dose is 200 mg taken twice a day (around 12 hours apart).
Estonian: Soovitatav annus on 200 mg kaks korda ööpäevas (umbes 12-tunnise vahega).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Vargatef on 21 November 2014.
Estonian: Euroopa Komisjon andis Vargatefi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. novembril 2014.
English: The full EPAR and risk management plan summary for Vargatef can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Vargatefi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Vargatef?
Estonian: Mis meetmed võetakse, et tagada Vargatefi ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Vargatef is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Vargatefi võimalikult ohutu kasutamine.
English: Other information about Vargatef
Estonian: Muu teave Vargatefi kohta
English: Vargatef is available as capsules (100 and 150 mg) to be taken by mouth, preferably with food.
Estonian: Vargatefi turustatakse suukaudsete kapslitena (100 ja 150 mg), mis võetakse sisse eelistatavalt koos toiduga.
English: If severe side effects persist, treatment should be permanently discontinued.
Estonian: Kui tõsised kõrvalnähud püsivad, tuleb ravi püsivalt lõpetada.
English: In addition, the company that markets Vargatef will conduct studies to find ways to identify those patients who are most likely to benefit from treatment with the medicine.
Estonian: Peale selle viib Vargatefi turustav ettevõte läbi uuringud, et leida viise nende patsientide kindlakstegemiseks, kellel oleks kõige suurema tõenäosusega sellest ravimist kasu.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Vargatef's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Vargatefi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: What is Vargatef and what is it used for?
Estonian: Mis on Vargatef ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Vargatef.
Estonian: See on ravimi Vargatef Euroopa avaliku hindamisaruande kokkuvõte.
English: These enzymes can be found in certain receptors (such as VEGF, FGF and PDGF receptors) on the surface of cancer cells and on the cells of the surrounding tissue (e.g. blood vessel), where they activate several processes including cell division and the growth of new blood vessels.
Estonian: Neid ensüüme leidub teatud retseptorites (nagu VEGF-, FGF- ja PDGF-retseptorid) vähirakkude pinnal ja ümbritseva koe rakkudel (nt veresooned), kus need aktiveerivad mitmeid protsesse, sh rakkude jagunemist ja uute veresoonte kasvu.
English: Treatment with Vargatef may continue after stopping docetaxel, for as long as the disease improves or remains stable and the side effects are tolerable.
Estonian: Ravi Vargatefiga võib jätkata pärast dotsetakseeli võtmise lõpetamist, kuni patsiendi seisund paraneb või püsib stabiilsena ja kõrvalnähud on talutavad.
English: By blocking these enzymes, nintedanib helps to reduce the growth and spread of the cancer and to cut off the blood supply that keeps cancer cells growing.
Estonian: Kõnealuseid ensüüme blokeerides takistab nintedaniib vähi kasvu ja levikut ning peatab vähirakkude kasvu toetava verevarustuse.
English: Why is Vargatef approved?
Estonian: Miks Vargatef heaks kiideti?
English: If severe side effects develop, the doctor may decide to interrupt treatment with Vargatef and resume it at a lower dose.
Estonian: Kui tekivad tõsised kõrvalnähud, võib arst otsustada katkestada ravi Vargatefiga ja jätkata seda väiksema annusega.
English: Vargatef is used to treat a type of non-small cell lung cancer called ‘adenocarcinoma', when the cancer is locally advanced, metastatic (when cancer cells have spread from the original site to other parts of the body) or locally recurrent (when the cancer has come back in the same area).
Estonian: Vargatefi kasutatakse teatud tüüpi mitteväikerakk-kopsuvähi adenokartsinoomi raviks, kui vähk on paikselt kaugelearenenud, metastaatiline (kui vähirakud on levinud algsest tekkekohast organismis ka mujale) või paikselt korduv (vähk on samas kohas taastunud).
English: The most common side effects with Vargatef (which may affect more than 1 in 10 people) include diarrhoea, vomiting and increased blood levels of certain liver enzymes (a sign of possible liver problems).
Estonian: Vargatefi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on kõhulahtisus, oksendamine ja teatud maksaensüümide sisalduse suurenemine veres (märk võimalikest maksaprobleemidest).
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom cycle, Vargatef is given on days 2 to 21 with docetaxel being given on day 1.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: Vargatef must not be used in patients who are hypersensitive (allergic) to nintedanib, peanut or soya, or any of the other ingredients.
Estonian: Vargatefi ei tohi kasutada patsiendid, kes on nintedaniibi, maapähkli või soja või ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: For the full list of all side effects and restrictions with Vargatef, see the package leaflet.
Estonian: Vargatefi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The medicine is used in combination with a chemotherapy medicine called docetaxel in patients who have already received previous treatment with chemotherapy.
Estonian: Ravimit kasutatakse kombinatsioonis keemiaravi ravimi dotsetakseeliga patsientidel, kes on juba saanud keemiaravi.
English: The CHMP noted that Vargatef was effective at slowing down disease progression and prolonging life in the subgroup of patients with non-small cell lung cancer of the adenocarcinoma type.
Estonian: Inimravimite komitee märkis, et Vargatef aeglustas tõhusalt haiguse progresseerumist ja pikendas elulemust adenokartsinoomi tüüpi mitteväikerakk-kopsuvähiga patsientide alarühmas.
English: In a main study involving 1,314 patients with advanced or recurrent non-small cell lung cancer that did not respond to a previous treatment, Vargatef taken in combination with docetaxel was shown to be more effective than docetaxel alone at delaying progression of the cancer.
Estonian: Põhiuuringus, milles osales 1314 kaugelearenenud või korduva mitteväikerakk-kopsuvähiga patsienti, kelle eelnev ravi ei andnud tulemusi, osutus vähi progresseerumise edasilükkamisel koos dotsetakseeliga manustatud Vargatef tõhusamaks kui ainult dotsetakseel.
English: Progression-free survival (the time patients lived without their disease getting worse) was 3.5 months in patients receiving Vargatef plus docetaxel, compared with 2.7 months in patients receiving docetaxel alone.
Estonian: Progressioonivaba elulemus (aeg, mille kestel patsiendid elasid haiguse süvenemiseta) oli 3,5 kuud patsientidel, kes said Vargatefi ja dotsetakseeli, võrreldes 2,7 kuuga patsientidel, kes said ainult dotsetakseeli.
English: Because Vargatef must not be given on the same day as docetaxel and because docetaxel is given on day 1 of a 21-day treatment
Estonian: Et Vargatefi ei tohi manustada samal päeval kui dotsetakseeli ja et dotsetakseeli manustatakse 21-päevase ravitsükli
English: It is not intended to provide practical advice on how to use Vargatef.
Estonian: Hindamisaruandes ei anta Vargatefi kasutamise praktilisi nõuandeid.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vargatef, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Vargatefi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Vargatef can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
Estonian: Ravi tohib alustada ning jälgida ainult vähiravimite kasutamises kogenud arst.
English: The active substance in Vargatef, nintedanib, blocks the activity of some enzymes known as tyrosine kinases.
Estonian: Vargatefi toimeaine nintedaniib blokeerib mõningate türosiinikinaasidena tuntud ensüümide toime.
English: In addition, Vargatef led to an improvement in overall survival (how long patients lived) in the subgroup of patients with non-small cell lung cancer of the adenocarcinoma type: overall survival was 12.6 months in patients treated with Vargatef plus docetaxel, compared with 10.3 months in patients treated with docetaxel alone.
Estonian: Peale selle paranes Vargatefiga ka üldine elulemus (kui kaua patsiendid elasid) adenokartsinoomi tüüpi mitteväikerakkkopsuvähiga patsientide alarühmas: Vargatefi ja dotsetakseeliga ravitud patsientide üldine elulemus oli 12,6 kuud võrreldes 10,3 kuuga ainult dotsetakseeliga ravitud patsientidel.
English: For practical information about using Vargatef, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Vargatefi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Regarding its safety, although more side effects were reported in patients treated with Vargatef plus docetaxel than in those treated with docetaxel alone, the side effects were considered manageable with dose reductions, supportive treatments and treatment interruptions.
Estonian: Kuigi Vargatefi ja dotsetakseeliga ravitud patsientidel teatati rohkematest kõrvalnähtudest võrreldes nendega, keda raviti ainult dotsetakseeliga, peeti kõrvalnähte ohutuse seisukohast ohjatavateks annuse vähendamise, toetava ravi ja ravi katkestamisega.
English: What are the risks associated with Vargatef?
Estonian: Mis riskid Vargatefiga kaasnevad?
English: For more information about treatment with Vargatef, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Vargatefiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How does Vargatef work?
Estonian: Kuidas Vargatef toimib?
English: Vargatef is a cancer medicine used to treat adults with a type of lung cancer known as non-small cell lung cancer.
Estonian: Vargatef on vähiravim, mida kasutatakse teatud tüüpi kopsuvähiga, mida nimetatakse mitteväikerakkkopsuvähiks, täiskasvanud patsientide raviks.
English: What benefits of Vargatef have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vargatefi kasulikkus?
English: How is Vargatef used?
Estonian: Kuidas Vargatefi kasutatakse?
English: Vargatef contains the active substance nintedanib.
Estonian: Vargatefi toimeaine on nintedaniib.
English: The period of protection is 8 weeks.
Estonian: Kaitse kestab 8 nädalat.
English: These reactions are very rare (affecting less than 1 bird in 10,000).
Estonian: Selliseid reaktsioone esineb väga harva (vähem kui 1 linnul 10 000-st).
English: This will help protect them against infectious bronchitis.
Estonian: See aitab neid infektsioosse bronhiidi eest kaitsta.
English: The Committee recommended that a further overdose study should be submitted.
Estonian: Komitee pidas vajalikuks üleannustamise kohta lisauuringu esitamist.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Estonian: Vaktsiinid n-ö õpetavad immuunsüsteemi (organismi loomulikke kaitsemehhanisme) kaitsma organismi haiguse eest.
English: The effectiveness of the vaccine was first studied in a number of laboratory studies in chickens.
Estonian: Vaktsiini efektiivsust kanadel uuriti kõigepealt mitmes laboriuuringus.
English: Hands and equipment should be washed and disinfected after vaccination to avoid spread of the virus.
Estonian: Viiruse leviku vältimiseks tuleb pärast vaktsineerimist pesta ja desinfitseerida käed ja varustus.
English: The vaccine is to be made up into a suspension for use.
Estonian: Kasutamiseks valmistatakse vaktsiinist suspensioon.
English: The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption or eggs or milk used for human consumption.
Estonian: Keeluaeg on alates ravimi manustamisest arvestatav aeg, mille jooksul ei tohi looma tappa ega tema liha või mune või piima tarvitada inimtoiduks.
English: This summary was last updated in July 2014.
Estonian: Kokkuvõtte viimane uuendus: 07-2014.
English: The laboratory studies showed that the vaccine had its full effect by three weeks and that protection lasted for eight weeks; protection was not affected by antibodies transmitted from the mother.
Estonian: Laboriuuringud näitasid, et vaktsiin avaldas täielikku mõju 3. nädalaks ja kaitse kestis 8 nädalat; kaitset ei mõjutanud maternaalsed antikehad.
English: If vaccinating by spray masks with eye protection should be worn when handling the product.
Estonian: Pihustamismeetodil vaktsineerimise korral tuleb ravimi käsitsemisel kanda silmi kaitsvat maski.
English: Live avian infectious bronchitis virus strain D388
Estonian: lindude infektsioosse bronhiidi elusviiruse tüvi D388
English: Nobilis IB Primo QX must not be given to birds which are laying eggs or within 4 weeks before the start of the laying period.
Estonian: Nobilis IB Primo QX-i ei tohi manustada munevatele lindudele ega 4 nädala jooksul enne munemisperioodi algust.
English: The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Estonian: Ravimi kasulikkuse ja riski suhe on käesoleva Euroopa avaliku hindamisaruande teadusliku arutelu jaotises.
English: The vaccine is given to chickens from 1 day of age or older by spraying onto the chickens or by applying drops into the eyes or nostrils.
Estonian: Vaktsiini manustatakse kanadele alates 1. elupäevast ja vanematele; seda pihustatakse kanadele või tilgutatakse neile silma või ninaavasse.
English: In the future if the animals are exposed to the virus the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad hiljem viirusega uuesti kokku, tekivad antikehad kiiremini.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Nobilis IB Primo QX on 4 September 2014.
Estonian: Euroopa Komisjon andis Nobilis IB Primo QX-i müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 4. septembril 2014.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobilis IB Primo QX exceed the risks for the approved indication and recommended that Nobilis IB Primo QX be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et heakskiidetud näidustusel on Nobilis IB Primo QX-i kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda Nobilis IB Primo QX-i müügiloa.
English: The purpose of the studies was to establish how long it took for chickens to be fully protected, the length of time protection lasts against infectious bronchitis due to QX-like variants, as well as the influence of maternal antibodies (transmitted from the mother) on the effectiveness of the vaccine.
Estonian: Uuringute eesmärk oli kindlaks teha, kui ruttu tekib kanadel täielik kaitse, kui kaua kestab kaitse QX-i laadsete variantide põhjustatud infektsioosse bronhiidi vastu ja milline on maternaalsete antikehade mõju vaktsiini efektiivsusele.
English: The avian infection bronchitis virus in Nobilis IB Primo QX has been attenuated (weakened) so that it does not cause disease.
Estonian: Nobilis IB Primo QX-is sisalduv lindude infektsioosse bronhiidi viirus on atenueeritud (nõrgestatud), et see ei põhjustaks haigust.
English: Nobilis IB Primo QX is a veterinary vaccine that contains live attenuated (weakened) avian infectious bronchitis virus strain D388.
Estonian: Nobilis IB Primo QX on veterinaarvaktsiin, mis sisaldab lindude infektsioosse bronhiidi elus atenueeritud (nõrgestatud) viiruse tüve D388.
English: In a second study 42 broiler chickens were spray vaccinated at 1 day old and challenged 3 weeks after vaccination with a QX strain of the virus.
Estonian: Teises uuringus vaktsineeriti pihustamismeetodil 42 broilerit nende 1. elupäeval ja 3 nädalat pärast vaktsineerimist nakatati neid katseliselt viiruse QX-i tüvega.
English: After vaccination a mild short lived reaction in the airways, including a nasal discharge, may occur for at least 10 days.
Estonian: Pärast vaktsineerimist võib vähemalt 10 päeva jooksul esineda kerge lühiajaline reaktsioon hingamisteedes, sh eritis ninaavadest.
English: Nobilis IB Primo QX is used to protect chickens against viral infectious bronchitis caused by strains of infectious bronchitis virus known as QX-like variants, such as strain D388.
Estonian: Nobilis IB Primo QX-i kasutatakse kanade kaitsmiseks viirusliku infektsioosse bronhiidi eest, mida tekitavad infektsioosse bronhiidi viiruse tüved (QX-i laadsed variandid), nagu tüvi D388.
English: In the first study broiler chickens (chickens bred for meat) were spray vaccinated with both Nobilis IB Primo QX and Nobilis IB Ma5, a vaccine against a Massachusetts strain of infectious bronchitis virus.
Estonian: Esimeses uuringus vaktsineeriti broilerid (lihakanad) pihustamismeetodil nii Nobilis IB Primo QX-iga kui ka Nobilis IB Ma5-ga, mis on infektsioosse bronhiidi viiruse Massachusettsi tüve vastane vaktsiin.
English: Two groups of 28 birds were challenged with the virus 3 weeks after vaccination, one group with a QX strain and the second group with another strain called M41.
Estonian: 3 nädalat pärast vaktsineerimist nakatati viirusega kaht katserühma (kummaski 28 lindu), üht rühma QX-i tüvega ja teist rühma M41 tüvega.
English: The effectiveness of Nobilis IB Primo QX was investigated in two field studies.
Estonian: Nobilis IB Primo QX-i efektiivsust uuriti kahes väliuuringus.
English: In the first field study 100% of the birds vaccinated with Nobilis IB Primo QX mixed with Nobilis IB Ma5 were protected from the QX strain and 90% were protected from M41, compared with none of the unvaccinated birds.
Estonian: Esimeses väliuuringus kaitses Nobilis IB Primo QX-i ja Nobilis IB Ma5 kombinatsioon QX-i tüve eest 100% vaktsineeritud lindudest ja M41 eest oli kaitstud 90% vaktsineeritud lindudest võrreldes vaktsineerimata lindudega, kellest ükski ei olnud kaitstud.
English: The withdrawal period for Nobilis IB Primo QX for chickens is zero days.
Estonian: Nobilis IB Primo QX-i keeluaeg kanade puhul on 0 päeva.
English: The second field study showed 93% of the Nobilis IB Primo QX vaccinated birds and none of the unvaccinated birds to be protected from the challenge.
Estonian: Teises väliuuringus oli katselise nakatamise eest kaitstud 93% Nobilis IB Primo QX-iga vaktsineeritud lindudest ja vaktsineerimata lindudest ei olnud ükski kaitstud.
English: Nobilis IB Primo QX is a vaccine.
Estonian: Nobilis IB Primo QX on vaktsiin.
English: Control groups of birds were unvaccinated to show the effectiveness of the challenge.
Estonian: Katselise nakatamise efektiivsuse tõendajaks olid lindude kontrollrühmad, keda ei vaktsineeritud.
English: Nobilis IB Primo QX is available as a lyophilisate (freeze-dried powder) which may be supplied with a solvent.
Estonian: Nobilis IB Primo QX-i turustatakse lüofilisaadina (külmkuivatatud pulbrina) koos lahustiga või ilma.
English: When Nobilis IB Primo QX is given to chickens the animals' immune system recognises the virus as ‘foreign' and makes antibodies against it.
Estonian: Kui kanadele manustatakse vaktsiini, peab loomade immuunsüsteem viirust võõraks ja tekitab selle vastu antikehi.
English: What is Nobilis IB Primo QX?
Estonian: Mis on Nobilis IB Primo QX?
English: What is the risk associated with Nobilis IB Primo QX?
Estonian: Mis riskid Nobilis IB Primo QX-iga kaasnevad?
English: Other information about Nobilis IB Primo QX:
Estonian: Muu teave Nobilis IB Primo QX-i kohta
English: Why has Nobilis IB Primo QX been approved?
Estonian: Miks Nobilis IB Primo QX heaks kiideti?
English: How does Nobilis IB Primo QX work?
Estonian: Kuidas Nobilis IB Primo QX toimib?
English: Unvaccinated chicks were retained as controls to show the effectiveness of the challenge.
Estonian: Katselise nakatamise efektiivsuse tõendajaks olid vaktsineerimata kanad.
English: How has Nobilis IB Primo QX been studied?
Estonian: Kuidas Nobilis IB Primo QX-i uuriti?
English: What is Nobilis IB Primo QX used for?
Estonian: Milleks Nobilis IB Primo QX-i kasutatakse?
English: The potential risk for humans is unknown.
Estonian: Potentsiaalne risk inimesele ei ole teada.
English: Inadequate response
Estonian: Ebapiisav reaktsioon
English: At the request of the European Medicines Agency;
Estonian: • Euroopa Ravimiameti nõudel;
English: Currently available data are described in section 5.1 but no recommendation or posology can be made.
Estonian: Hetkel olemasolevad andmed on toodud lõigus 5.1, kuid soovitusi doseerimiseks ei anta.
English: Not relevant.
Estonian: Pole asjakohane.
English: (see section 6 ‘further information' where the full list of ingredients is provided).
Estonian: (Vt lõik 6 'Lisainfo', kus on toodud täielik koostisosade loetelu.)
English: Driving and using machines Not relevant.
Estonian: Autojuhtimine ja masinatega töötamine Ei ole asjakohane
English: They were considered so inert that testing was not required.
Estonian: Neid loetakse sel määral inertseteks, et katsetamist ei nõutud.
English: The duration of therapy is variable, but typically less than four days.
Estonian: Ravi kestus varieerub, kuid on harilikult lühem kui neli päeva.
English: Please tell your doctor if you (as the patient) or your child (as the patient) are taking or have recently taken or used any other medicines, including medicines obtained without a prescription.
Estonian: Palun informeerige oma arsti, kui teie (patsiendina) või teie laps (patsiendina) kasutab või on hiljuti kasutanud mingeid muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimid.
English: The lowest effective dose will be sought.
Estonian: Manustada tuleks kõige madalam efektiivne annus.
English: If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, even after you or your child leave the hospital, please tell your doctor.
Estonian: Kui ükskõik milline kõrvaltoimetest muutub tõsiseks või kui te märkate mõnda kõrvaltoimet, mida selles infolehes ei ole nimetatud, seda ka pärast teie või teie lapse haiglast lahkumist, palun rääkige sellest oma arstile.